Aprogen Biologics KRX:003060KOSPI
에이프로젠바이오로직스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days2
Articles tracked0since Sep 11
In Q2 2026, Aprogen Biologics reported revenue of ₩23.1bn, up 54.9% year on year, and an operating loss of ₩17.5bn. Aprogen Biologics (에이프로젠바이오로직스) appeared in 0 Korean news articles and 2 DART filings over the past seven days.
Aprogen Biologics quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩23.1bn | +54.9% | −₩17.5bn | −₩9.7bn |
| Q1 2026 | ₩21.6bn | +28.3% | −₩13.6bn | −₩4.6bn |
| Q4 2025 derived | ₩20.4bn | -7.6% | −₩16.0bn | −₩33.8bn |
| Q3 2025 | ₩21.1bn | +45.3% | −₩10.7bn | −₩24.5bn |
| Q2 2025 | ₩14.9bn | -1.9% | −₩18.0bn | −₩66.9bn |
| Q1 2025 | ₩16.8bn | +8.0% | −₩15.7bn | −₩43.1bn |
| Q4 2024 derived | ₩22.0bn | -2.9% | −₩16.0bn | −₩60.0bn |
| Q3 2024 | ₩14.5bn | -27.8% | −₩13.1bn | −₩15.5bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Aprogen Biologics top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Aprogen Biologics news Korean headlines
No articles yet.